THE **DAVIO 2** TRIAL:

Subgroup Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration

Carl D. Regillo, MD

On behalf of the DAVIO 2 trial investigators

Mid Atlantic Retina, Wills Eye Hospital Retina Service, Thomas Jefferson University, Philadelphia, PA, USA

Angiogenesis, Exudation, and Degeneration 2024

Interim data - database lock pending, final 12M data expected 2H 2024

Disclosures

Financial Disclosures

- Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Bausch and Lomb, Clearside, Cognition, EyePoint, Genentech, Iveric, Janssen, Kodiak, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Occuphire, Opthea, Ray, RegenXBio, Stealth, Thea, Zeiss

- Research grant support: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, Iveric, Janssen, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio

DAVIO 2: Phase 2 Randomized, Double-Masked, Parallel Trial of a Single EYP-1901 Treatment Compared to SoC in Previously Treated wAMD Patients

Primary end point: Combined mean change in BCVA at Weeks 28 and 32 (6 months after EYP-1901 injection)



Key inclusion/exclusion criteria

- Diagnosed with wAMD at any time
- History of documented response to anti-VEGF
- History of at least 2 injections in last 6 months
- BCVA range 85 to 35 letters (20/20 to 20/200)
- Excluded CST >350 µm, IRF >25 µm, RPED >400 µm

Criteria for supplemental injection

BCVA reduction of ≥5 letters from best on-study measurement due to wAMD AND increase in CST of ≥75 µm from lowest on-study measurement

OR

BCVA reduction of ≥10 letters from best on-study measurement due to wAMD

OR

Increase in CST of ≥100 µm from lowest on-study measurement from 2 consecutive visits

OR

Presence of new or worsening vision-threatening hemorrhage due to wAMD

BCVA, best corrected visual acuity; CST, central subfield thickness; IRF, intraretinal fluid; RPED, retinal pigment epithelium detachment; wAMD, wet age-related macular degeneration.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

DAVIO 2 Baseline Characteristics Well Balanced Across Arms

Baseline Characteristics (N = 156)	Aflibercept 2 mg q8W (n = 54)	EYP-1901 2 mg (n = 50)	EYP-1901 3 mg (n = 52)
Mean age, years (range)	75.9 (52-93)	76.4 (61-93)	75.4 (56-89)
Female, %	53.7%	64.0%	67.3%
Mean BCVA, ETDRS letters (range)	73.4 (41-85)	73.9 (52-84)	74.9 (46-85)
Mean CST, µm (range)	265.7 (178-348)	267.0 (192-400)	262.9 (186-345)
Median length of time for wAMD diagnosis prior to screening, months (range)	28.1 (2.4-273.8)	24.3 (2.4-168.1)	28.1 (2.4-145.3)
Mean number of injections in the 12 months prior to screening (range)*	**9.5 (2-12)**	**10.2 (2-13)**	**10.0 (2-13)**

*Normalized values using topline Table 9-1. Other data are from topline Tables 2 and 3.
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks; VEGF, vascular endothelial growth factor.

Primary End Point: EYP-1901 Statistically Non-inferior to SoC in Maintaining BCVA Over 32 Weeks



Data from topline Table 4-1. Error bars represent the standard deviation. BCVA units were ETDRS letters.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks; SoC, standard of care.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

CST Similar to SoC and No Sawtooth Pattern Over 32 Weeks with EYP-1901



Data from topline Table 6. Error bars represent the standard deviation. CST units were µm.
CST, central subfield thickness; q8W, every 8 weeks; SoC, standard of care.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

≥64% of Eyes Receiving EYP-1901 Were Supplemental Injection–Free Up to Week 32



Data from topline Table 7.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

≥83% of EYP-1901 Eyes Received 0-1 Supplemental Injections Weeks 8-32

EYP-1901–Treated Eyes Receiving Aflibercept Supplementation, Weeks 8-32



EYP-1901 2 mg (n = 50)

EYP-1901 3 mg (n = 52)

Eyes with Supplemental Injections Did Not Drive BCVA Outcomes

Mean Change in BCVA, All Eyes



Mean Change in BCVA vs Aflibercept 2 mg q8W

EYP-1901 2 mg	EYP-1901 3 mg
-0.3	-0.4

+1.3 (n = 53)
+1.0 (n = 48)
+0.9 (n = 52)

Mean Change in BCVA, Eyes Without Supplemental Injections



Mean Change in BCVA vs Aflibercept 2 mg q8W

EYP-1901 2 mg	EYP-1901 3 mg
+0.6	+0.1

+2.4 (n = 31)
+1.9 (n = 33)
+1.8 (n = 50)

Data from IA-SG01 Table 1. BCVA units were ETDRS letters.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W; every 8 weeks.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Eyes with Supplemental Injections Did Not Drive Anatomical Outcomes





Data from IA-SG01 Table 2. CST units were µm.
CST, central subfield thickness; q8W, every 8 weeks.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Baseline BCVA Had No Meaningful Impact on BCVA Outcomes

Mean Change in BCVA, Baseline BCVA <75



Mean Change in BCVA, Baseline BCVA ≥75



Data from IA-SG04 Table 1. BCVA units were ETDRS letters.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks.

Baseline BCVA Had No Meaningful Impact on CST Outcomes

Mean Change in CST, Baseline BCVA <75



Mean Change in CST, Baseline BCVA ≥75



Data from IA-SG04 Table 2. CST units were µm.
BCVA, best-corrected visual acuity; CST, central subfield thickness; q8W, every 8 weeks.

Duration of wAMD Diagnosis Had No Meaningful Impact on BCVA Outcomes

Mean Change in BCVA, Diagnosed <12 Months



Mean Change in BCVA, Diagnosed ≥12 Months



Data from IA-SG02 Table 1. BCVA units were ETDRS letters.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks; wAMD, wet age-related macular degeneration.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Duration of wAMD Diagnosis Had No Meaningful Impact on CST Outcomes

Mean Change in CST, Diagnosed <12 Months



Mean Change in CST, Diagnosed ≥12 Months



Data from IA-SG02 Table 2. CST units were µm.
CST, central subfield thickness; q8W, every 8 weeks; wAMD, wet age-related macular degeneration.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Comparison of Number of Historical Anti-VEGF Injections on BCVA Outcome

Mean Change in BCVA, ≤5 Historical Anti-VEGF Injections During Prior 12 Months



Mean Change in BCVA, ≥6 Historical Anti-VEGF Injections During Prior 12 Months



Data from IA-SG06 Table 1. BCVA units were ETDRS letters.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; q8W, every 8 weeks; VEGF, vascular endothelial growth factor.

Comparison of Number of Historical Anti-VEGF Injections on CST Outcome; No Sawtooth Pattern in Eyes Receiving EYP-1901

Mean Change in CST, ≤5 Historical Anti-VEGF Injections During Prior 12 Months



Mean Change in CST, ≥6 Historical Anti-VEGF Injections During Prior 12 Months



Data from IA-SG06 Table 2. CST units were µm.
CST, central subfield thickness; q8W, every 8 weeks; VEGF, vascular endothelial growth factor.

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Proposed EYP-1901 wAMD Phase 3 Trial – Similar to DAVIO 2

Randomized, Double-Masked, Aflibercept-Controlled Trial



- EYP-1901 dosing
- Per protocol scheduled visits/assessments
- Sham injection
- Per protocol aflibercept intravitreal injection
- Per protocol aflibercept every 8 weeks during study visit window

Key Inclusion/Exclusion Criteria

- Diagnosed with wAMD at any time
- History of documented response to anti-VEGF
- History of at least 2 injections in last 6 months
- BCVA range 85 to 35 letters (20/20 to 20/200)
- Excluded CST >350 µm, IRF >25 µm, RPED >400 µm

Key End Points

Primary end point:

- Mean change in BCVA at Week 52 and Week 56
- Non-inferiority margin 4.5 letters

Secondary end points:

- Safety
- Anti-VEGF injection burden reduction
- Supplement-free rate up to Week 56
- CST change

DAVIO 2 INTERIM DATA NOV23: DATABASE LOCK PENDING

Positive DAVIO 2 Data Supports Advancement to Non-Inferiority Phase 3 Pivotal Trials in wAMD

Phase 3 pivotal trial were designed based on Type C meeting with FDA Q4 2022 and consistent with subsequent wAMD draft guidance for non-inferiority clinical trials

- The Phase 3 non-inferiority trial design is similar to DAVIO 2 with the exception of:
  - Reinjection of EYP-1901 at six month intervals
  - Primary efficacy endpoint at 12 months (blended w52/56)
  - Safety data monitored for up to 24 months
  - EYP-1901 dosing likely 1 or 2 inserts (vs 2 or 3 in DAVIO 2)
- Two registration trials: parallel US and OUS
- Initiation of the first pivotal trial anticipated in 2H 2024

DAVIO 2 Trial Subgroup Data Supports Durability of EYP-1901 Up to 6 Months

Primary end point

- BCVA: Statistically non-inferior change vs aflibercept; stable over 6 months

Secondary end points

- Strong anatomical control: **<10 µm** OCT difference vs SoC **≥64%** of eyes supplemental injection–free at 6 months
- **≥85%** mean reduction in treatment burden vs prior 6 months

Subgroup assessments of EYP-1901

- Eyes without supplemental injections did just as well as total randomized subjects

  -Eyes with supplemental injections did not drive the visual and anatomical outcomes
- Visual and anatomical outcomes were not meaningfully influenced by differences in baseline BCVA, duration of wAMD diagnosis, or historical treatment burden
- These data demonstrate that EYP-1901 outcomes are consistent and durable in a variety of wAMD patient types

Ph2 DAVIO 2 12m readout H2 2024; DME first patient enrolled Jan 2024;
Ph2 NPDR topline mid-2024; Global Ph3 wAMD planned initiation H2 2024

AE, adverse event; BCVA, best corrected visual acuity; CST, central subfield thickness; DME, diabetic macular edema; H2, second half; IVT, intravitreal; OCT, optical coherence tomography; Q1, first quarter; SAE, serious adverse event; wAMD, wet age-related macular degeneration.